Myomo price target raised to $9.50 from $7.50 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Myomo (MYO) to $9.50 from $7.50 and keeps a Buy rating on the shares following the Q4 report. The firm expects 2025 to be “another record year “for Myomo as the company achieves “significant financial milestones.” The company plans to double its advertising spend to $6M in 2025, which should contribute significantly to new direct-to-patient sales, the analyst tells investors in a research note.